MedTrace Logo

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

NCT00158899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 424

Last updated 2017-05-30

No results posted yet for this study

Summary

The purpose of this clinical research study is to compare up to 3 doses of an investigational drug GW501516 to placebo (an inactive pill that looks like GW501516) to see if it is safe, well tolerated and effective in improving (raising) low levels of "good cholesterol", high-density lipoprotein cholesterol (HDLc), as compared to placebo.

Conditions

  • Dyslipidaemias
  • Dyslipidaemia

Interventions

DRUG

GW501516 oral tablets

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, MA · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • Belgium
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Lithuania
  • Netherlands
  • Norway
  • Portugal
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00158899 on ClinicalTrials.gov